MiPLA

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-07srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
5. 2026-09-07srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
6. 2026-09-07srcReturn of the lysergamides. Part III: Analytical characterization of ETH-LAD and 1P-ETH-LAD
7. 2026-09-07srcReturn of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)
8. 2026-09-07srcSeparating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA
9. 2026-09-07srcChemistry and Structure-Activity Relationships of Psychedelics.
10. 2026-09-07srcFlashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants
11. 2026-09-07srcIdentification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products
12. 2026-09-07srcAn animal model of schizophrenia based on chronic LSD administration: old idea, new results
13. 2026-09-07srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
14. 2026-09-07srcPharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
15. 2026-09-07srcMicrodosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
16. 2026-09-07srcIdentification of LSD Derivatives, 1cP-LSD, MIPLA and 1B-LSD in Illegal Products as Paper Sheet
17. 2026-09-07srcHallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
18. 2026-09-07srcChallenges in Drug Surveillance: Strengthening the Analysis of New Psychoactive Substances by Harmonizing Drug Checking Services in Proficiency Testing
19. 2026-09-07srcd-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
20. 2026-09-07srcForensic Aspects of Designer LSD Analogs Identification by GC-MS (EI) and UV Spectroscopy
21. 2026-09-07srcHallucinogen-Induced Persisting Perception Disorder: A Case Report
22. 2026-09-07srcLysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)
23. 2026-09-07srcMonoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.
24. 2026-09-07srcLSD and structural analogs: pharmacological evaluation at D1 dopamine receptors
25. 2026-09-07srcStereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes
26. 2026-09-07srcDrug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives
27. 2026-09-07srcLysergic Acid Amides (US Patent 2997470A)
28. 2026-09-07srcMiPLA - PsychonautWiki
29. 2026-09-07srcThe Big & Dandy MIPLA (Methylisopropyllysergamide) Thread
30. 2026-09-07srcMiPLA (solution) - Product Datasheet
31. 2026-09-07srcMiPLA Product Data - VulcanChem
32. 2026-09-04issueIssued emergency
33. 2026-09-04issueIssued info_card
34. 2026-09-04issueIssued notice
35. 2026-06-04proposal27 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
36. 2026-06-04publicationPublication — backfill
37. 2026-05-03revisionRevision 1
38. 2026-05-03absenceSearched ClinicalTrials.gov for "MiPLA lysergamide psychedelic" — no results
39. 2026-05-03genGeneration — pipeline-v5pipeline-v5
40. 2026-05-03rungeneration run

The same entries, as forms: six forms.